Viva Biotech and Silexon AI Forge Strategic Collaboration to Advance AI-Driven Drug Discovery

Viva Biotech and Silexon Sign Strategic Cooperation Agreement for New Drug R&DRecently, Viva Biotech and Silexon entered into a strategic cooperation agreement for new drug research and development. Under the agreement, the two parties will collaborate on innovative drug R&D to provide the industry with a next-generation platform for hit and lead compound discovery and optimization based on Artificial Intelligence (AI). This partnership will also empower Viva Biotech’s unique Equity-for-Service (EFS) ecosystem with innovative momentum.

Regarding this collaboration, Zeng Hainian, CEO of Silexon AI, stated: “As people pursue healthier lifestyles and the demand for new and effective drugs becomes increasingly urgent, innovative drug development faces numerous challenges. Viva Biotech has extensive experience in structure-based drug discovery, while Silexon AI is based on”Big Data“By collaborating with AI4D, an integrated innovative drug R&D platform powered by artificial intelligence, and Viva Biotech’s SBDD and FBDD new drug screening platforms, we leverage multiple technological approaches to facilitate the discovery and optimization of hit and lead compounds. We anticipate that this partnership will effectively enhance the efficiency of new drug development and provide greater support to the industry.”

Dr. Ye Zhixiong, Chief Scientific Officer of Viva Biotech, stated, “We are delighted to enter into this strategic collaboration with Silexon. Silexon, based onBig Data"The integrated platform for innovative drug R&D, powered by AI technology development, leverages artificial intelligence to enhance the discovery and optimization of hit and lead compounds. This is expected to significantly improve the efficiency and success rate of key stages in drug discovery and development, thereby promoting the upgrading and iteration of new drug discovery technologies. It is believed that the AI4D technology platform will complement Viva Biotech’s structure-based comprehensive drug discovery platform, creating synergies with its EFS business to jointly accelerate and empower innovative drug R&D."Bio ValleyBioon.com）